In their recent review, Punt and Eggermont [1] state that "combined data from low-dose IFN-α [interferon-α] trials does not suggest a benefit in … DFS [disease-free survival]". This conclusion is inconsistent with the results of a metaanalysis of these trials [2] . It is surprising that Punt and Eggermont [1] do not mention this study, especially as the latter was an author on the meta-analysis. The meta-analysis indicates a significant benefit for IFN-α on DFS: odds ratio (OR) = 0.87, 95% confidence interval (CI) 0.79-0.96, P = 0.007. The corresponding OR for high-dose trials was 0.76 (95% CI 0.65-0.89, P = 0.0009). Overall, there is good evidence that IFN−α reduces recurrence (OR = 0.84, 95% CI 0.77-0.92, P = 0.0001), but the appropriate test for interaction (P = 0.2) provides no clear evidence that high-dose is more effective than low-dose ( Figure 1) .
It is important not to interpret P values over simplistically, i.e. P <0.05 means that treatment is beneficial/harmful and P >0.05 means that it is not. The conventional level of significance is an arbitrary cut-off on a continuum of probability. It is preferable, and should lead to less misinterpretation, to use estimation and confidence intervals [3] and express trial results as ORs with CIs, as in Figure 1 . Most IFNα trials were underpowered to detect moderate, but potentially worthwhile, benefits (∼800 patients are needed to detect a difference of 10% at P = 0.05 with 80% power) and may have given 'false negative' results. (Perhaps the best oncology example is tamoxifen in breast cancer-most individual trials showed no significant benefit, yet meta-analysis demonstrated an incontrovertible benefit that led to a great increase in usage worldwide [4] .) Punt and Eggermont [1] report that "a UKCCCR trial … shows no differences in DFS" [5] . However, the OR for DFS in this trial (0.88) is entirely consistent with that observed for low-dose trials in the meta-analysis (OR = 0.87), so the absence of a significant difference (P = 0.2) cannot be taken as evidence that there is no difference. It is important to distinguish between "evidence of lack of effect" and "lack of evidence of effect"-the latter is more frequent given the small size of many trials. Alternatively, when several trials have addressed a particular question, it is likely that some will, by chance, overestimate the true effect and give false positive Figure 1 . Meta-analysis of trials of IFN−α as adjuvant therapy for melanoma. The endpoint is disease-free survival. Trials are grouped into high-and low-dose categories and the results are presented in standard meta-analysis format with a test for interaction between the two groups. The totals in the control column are less than the sum of the two separate groups since control patients in one three-arm trial are only counted once in the overall total. O-E, observed minus expected; Var., variance; OR, odds ratio; CI, confidence interval; Odds Redn., odds reduction; SD, standard deviation.
results. The E1684 high-dose trial may be an instance of this, since a survival advantage was not seen in the confirmatory E1690 study (see Punt and Eggermont [1] for references).
The use of qualitative scoring systems (i.e. simple '+' or '-' depending on statistical significance or not) to review treatment efficacy is unsatisfactory and potentially misleading. It is preferable to employ the quantitative methods of systematic meta-analysis. Thus, we agree with Punt and Eggermont that the evidence for a survival benefit with IFN−α remains unclear, at all doses, and that a further meta-analysis of all the trials should be undertaken. This should use individual patient data, thereby permitting the inclusion of more mature data, with longer follow-up, than are available in most publications and investigation of whether particular types of melanoma patient benefit from adjuvant IFN-α therapy. 
